ACT

Shell Veteran Colin Crooks Appointed CEO of Environmental Solutions Provider ACT

Retrieved on: 
Tuesday, January 23, 2024

AMSTERDAM, Jan. 23, 2024 /PRNewswire/ -- Colin Crooks, former CEO and Board Chair of Shell Energy Retail and most recently Shell Senior Vice President of Renewables and Energy Solutions Europe, will join ACT Group as CEO effective April 1, 2024.

Key Points: 
  • AMSTERDAM, Jan. 23, 2024 /PRNewswire/ -- Colin Crooks, former CEO and Board Chair of Shell Energy Retail and most recently Shell Senior Vice President of Renewables and Energy Solutions Europe, will join ACT Group as CEO effective April 1, 2024.
  • Crooks succeeds Bram Bastiaansen, who co-founded ACT in 2009 and grew the company into a leading global environmental solutions provider.
  • "Bram and Jaap Janssen built ACT into a highly regarded partner for companies, delivering environmental solutions backed by scientific integrity.
  • Crooks brings decades of experience in energy solutions, including a decade in renewable energy, to ACT.

Shell Veteran Colin Crooks Appointed CEO of Environmental Solutions Provider ACT

Retrieved on: 
Tuesday, January 23, 2024

AMSTERDAM, Jan. 23, 2024 /PRNewswire/ -- Colin Crooks, former CEO and Board Chair of Shell Energy Retail and most recently Shell Senior Vice President of Renewables and Energy Solutions Europe, will join ACT Group as CEO effective April 1, 2024.

Key Points: 
  • AMSTERDAM, Jan. 23, 2024 /PRNewswire/ -- Colin Crooks, former CEO and Board Chair of Shell Energy Retail and most recently Shell Senior Vice President of Renewables and Energy Solutions Europe, will join ACT Group as CEO effective April 1, 2024.
  • Crooks succeeds Bram Bastiaansen, who co-founded ACT in 2009 and grew the company into a leading global environmental solutions provider.
  • "Bram and Jaap Janssen built ACT into a highly regarded partner for companies, delivering environmental solutions backed by scientific integrity.
  • Crooks brings decades of experience in energy solutions, including a decade in renewable energy, to ACT.

Humane Society of Missouri's Animal Cruelty Task Force Rescues 55 Dogs, Recovers 20 Deceased Animals from Horrific Conditions in Stone County, Missouri

Retrieved on: 
Saturday, January 20, 2024

ST. LOUIS, Jan. 20, 2024 /PRNewswire/ -- Late yesterday afternoon, the Humane Society of Missouri's (HSMO) Animal Cruelty Task Force (ACT) – one of the nation's largest animal-rescue and disaster-response teams – rescued 55 dogs, mostly large-breed mixes, from a property in Stone County, Missouri. The rescued dogs were transported to HSMO's Macklind headquarters in St. Louis to receive health evaluations and emergency veterinary treatment. The carcasses of 15 dogs and five goats were also found on the property, but it was unclear whether the animals died of starvation or froze to death. The remains were removed, and necropsies will be performed.

Key Points: 
  • The rescued dogs were transported to HSMO's Macklind headquarters in St. Louis to receive health evaluations and emergency veterinary treatment.
  • The emergency rescue was prompted by calls on Friday morning from concerned residents and the Stone County Sheriff's office.
  • Members of the Animal Cruelty Task Force deployed immediately due to the animals' reported conditions and the dangerous cold.
  • To report an animal that may be in danger or is suffering from neglect or abuse, call the local police and the Humane Society of Missouri's Animal Cruelty Hotline at 314-647-4400.

AceIt by Juni Learning Launches DSAT Dash: A Free 6-Week Challenge to Help High Schoolers Ace the Digital SAT

Retrieved on: 
Thursday, January 18, 2024

SAN FRANCISCO, Jan. 18, 2024 /PRNewswire-PRWeb/ -- 77% of American students feel overwhelmed by tests. AceIt, an AI-powered SAT and ACT prep platform created by Juni Learning, is prepared for this figure to increase as students begin studying for the new, entirely digital format of many standardized tests, like the SAT. This is why AceIt is introducing the 'DSAT Dash', a completely free 6-week challenge designed to support students in this transition and equip them with the skills and knowledge needed to ace the new Digital SAT.

Key Points: 
  • AceIt by Juni Learning unveils 'DSAT Dash': A Free, Innovative 6-week Digital Challenge transforming SAT Prep by offering high schoolers a unique blend of tools and community support to excel in the new era of digital testing
    SAN FRANCISCO, Jan. 18, 2024 /PRNewswire-PRWeb/ -- 77% of American students feel overwhelmed by tests.
  • AceIt, an AI-powered SAT and ACT prep platform created by Juni Learning , is prepared for this figure to increase as students begin studying for the new, entirely digital format of many standardized tests, like the SAT.
  • This is why AceIt is introducing the 'DSAT Dash', a completely free 6-week challenge designed to support students in this transition and equip them with the skills and knowledge needed to ace the new Digital SAT.
  • With the DSAT Dash, AceIt is opening the doors for all students to get free, engaging Digital SAT support while creating a community to foster collaboration and motivation as students navigate through a big transition to the entirely Digital SAT

RALIANCE Awards $300,000 in Grants for Projects to End Sexual Harassment, Misconduct and Abuse

Retrieved on: 
Thursday, January 18, 2024

WASHINGTON, Jan. 18, 2024 /PRNewswire/ -- RALIANCE, a trusted adviser for organizations committed to creating equitable, respectful, and safe environments, announced today that it will award a total of $300,000 in grants to six organizations across the United States that are entrenched in their communities working to support survivors and prevent sexual harassment, misconduct, and abuse. In 2022, RALIANCE and the National Football League (NFL) announced the renewal of its grant partnership to expand RALIANCE's efforts to offer more resources and grant funding to organizations at the intersection of sexual misconduct prevention and social justice.

Key Points: 
  • "RALIANCE is honored to welcome these exceptional grantees to our growing roster of organizations making positive impacts in their communities," said Yolanda Edrington, a Managing Partner at RALIANCE.
  • "This year's cohort stands out in the innovative ways many are using the arts and creativity as a transformative tool.
  • Through this latest round of funding, RALIANCE will support initiatives in new communities, spanning various geographic regions across the U.S. and territories.
  • We are excited to partner with RALIANCE in our shared vision of ending sexual violence, which includes child sexual abuse.

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

Retrieved on: 
Thursday, January 18, 2024

"Finally, being able to secure a non-dilutive royalty capital solution from XOMA to focus our resources on Niyad while still being able to participate in the DSUVIA royalty and milestone stream is an ideal transaction for Talphera.

Key Points: 
  • "Finally, being able to secure a non-dilutive royalty capital solution from XOMA to focus our resources on Niyad while still being able to participate in the DSUVIA royalty and milestone stream is an ideal transaction for Talphera.
  • The total additional capital available to the Company should all outstanding Series A and Series B common stock warrants be exercised is $14.4 million.
  • Talphera has completed a partial monetization of its DSUVIA royalties and milestones with XOMA for $8 million.
  • Talphera expects the committed funding to provide sufficient capital to fund Talphera through a potential approval of Niyad, targeted in the first half of 2025.

Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients

Retrieved on: 
Wednesday, January 17, 2024

Study suggests benefits in weight gain, respiration, and survival

Key Points: 
  • Study suggests benefits in weight gain, respiration, and survival
    JERUSALEM, Jan. 17, 2024 /PRNewswire/ -- Immunity Pharma , a clinical-stage neurology-focused biopharmaceutical company, today announced positive top line results from the Phase 2a trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients.
  • IPL344 treated patients showed a mean slope of decline in ALSFRS-R of -0.53, equating 48% slower disease progression (p=0.028).
  • "These early-stage data support further development of IPL344 as a treatment for ALS, and merit further investigation in a large number of participants.
  • We intend to progress PL344 to a pivotal clinical trial in ALS," said Immunity's CEO, Eran Ovadia.

Aduro Clean Technologies Presents at CEM AlphaNorth Capital Event and Extends Engagement with Arrowhead Business and Investment Decisions

Retrieved on: 
Tuesday, January 16, 2024

During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.

Key Points: 
  • During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.
  • The Company has also extended its engagement with Arrowhead Business and Investment Decisions, LLC (“Arrowhead”), originally announced on May 4, 2023 , regarding the provision of investor relations services to the Company.
  • The Company is pleased to be participating in the CEM AlphaNorth Capital Event and to have the opportunity to showcase its recent achievements and discuss future plans with investors.
  • The Company is also pleased to announce that it has extended its marketing and investor relations agreement with Arrowhead.

Exro Releases Q1 2024 Letter to Shareholders

Retrieved on: 
Monday, January 15, 2024

CALGARY, AB, Jan. 15, 2024 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro"), a leading clean-technology company that develops new generation power-control electronics that expand the capabilities of electric motors and batteries, is pleased to announce the release of a Q1 2024 letter to shareholders.

Key Points: 
  • CALGARY, AB, Jan. 15, 2024 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro"), a leading clean-technology company that develops new generation power-control electronics that expand the capabilities of electric motors and batteries, is pleased to announce the release of a Q1 2024 letter to shareholders.
  • Indicated in our December shareholder letter and as tradition holds, this Q1 2024 shareholder letter outlines our strategic focus areas for 2024 and references notable strides completed over the past twelve months.
  • Exro recently held in-person management work outs to chart out the strategic plans for the 2024 launch and marketing of the E-Beam Axle program.
  • As we enter 2024 Exro continues to execute its capital markets strategy to ensure we are adequately funded to deliver to customers and shareholders.

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

Retrieved on: 
Wednesday, January 10, 2024

ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, small molecule stabilizer of transthyretin (TTR).

Key Points: 
  • ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, small molecule stabilizer of transthyretin (TTR).
  • Findings presented in the NEJM support acoramidis as an effective and safe treatment option for patients with ATTR-CM and reinforce the hypothesis that greater stabilization of TTR may be associated with improved clinical outcomes.
  • BridgeBio has also presented additional detailed results from ATTRibute-CM at the European Society of Cardiology Congress 2023 in August and at the American Heart Association Scientific Sessions 2023 in November .
  • The Company submitted a New Drug Application to the U.S. FDA in 2023 and intends to submit additional marketing authorization applications to regulatory bodies in 2024.